Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia.
Neily ZakiyahRano Kurnia SinurayaArif S W KusumaAuliya Abdurrohim SuwantikaKeri LestariPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
Based on the current price in Indonesia, sacubitril/valsartan can be considered a cost-effective option, although this depends heavily on the willingness to pay threshold. Further studies that incorporate real-world evidence with sacubitril/valsartan are needed to inform the decision-making process.